Skip to content

Clinical trials

Phase 1/2 trials in the Netherlands

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Phase: Phase 1/2 Country / region: Netherlands Clear all

513 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20003
20013
20021
20036
20042
20059
200610
200711
200814
200916
201013
201114
201216
201324
201425
201526
201631
201721
201831
201929
202036
202133
202232
202329
202434
202530
202612

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed226
Recruiting95
Terminated76
Active, not recruiting53
Unknown status43
Withdrawn9
Not yet recruiting7
Enrolling by invitation2
Suspended2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Radboud University Medical Center32
University Medical Center Groningen23
Bristol-Myers Squibb20
Novartis Pharmaceuticals17
The Netherlands Cancer Institute17
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)16
Merck Sharp & Dohme LLC13
AstraZeneca11
Erasmus Medical Center11
Leiden University Medical Center11

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Neoplasms41
Carcinoma, Non-Small-Cell Lung35
Colorectal Neoplasms29
Neoplasm Metastasis22
Melanoma21
Recurrence21
Ovarian Neoplasms19
Breast Neoplasms18
Leukemia, Myeloid, Acute18
Precursor Cell Lymphoblastic Leukemia-Lymphoma17

Trials

Showing 26 to 50 of 513. Each trial links to its page on Pharma Observatory.

413 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.